Judge holds up Teva's $85M opioid settlement, sinking shares back to pre-2000 levels

red traffic stop light
A judge has put a hold on Teva's $85 million opioid settlement in Oklahoma to seek more information. (Unsplash)

Teva made headlines late last month when it inked an $85 million settlement with Oklahoma prosecutors over opioid mismarketing allegations—even after CEO Kåre Schultz said the company wouldn't strike big settlement deals in the ongoing opioid litigation.

Now, an Oklahoma judge in the state has refused to sign off on the deal until he gets more information about how it complies with a new state law, AP reports.

Judge Thad Balkman on Monday ordered prosecutors and Teva's attorneys to provide information about how the deal conforms to the new law, which requires settlement funds to disburse directly to the state's treasury, the news service reports.

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

Lawmakers in the state passed that law after Purdue Pharma and its founding family inked a $270 million opioid settlement, which Judge Balkman approved.

In a note to clients, Wells Fargo analyst David Maris wrote that the news "sounds like more of an administrative burden rather than a threat to the actual settlement." He noted that Teva's stock was down 7% Wednesday morning on the news, but that "seems overdone."

RELATED: Teva shares hit 19-year low after opioid settlement, analyst downgrades

The decline does show just how closely Teva investors are watching the legal headlines. After the company agreed on the $85 million settlement late last month, Teva shares sank to a 19-year low.

Teva faces nationwide opioid litigation—which could multiply that settlement significantly—and other legal challenges, including price-fixing allegations. On Wednesday, the company's shares were trading at levels last seen in 1999.

Meanwhile, Oklahoma's lawsuit against Johnson & Johnson continues. The state says J&J “manipulated” residents into believing their pain drugs were safe to use for long periods of time. Prosecutors aim to recoup “catastrophic” damages the state has suffered as misleading marketing fueled the opioid addiction crisis. J&J has argued it marketed opioid painkillers responsibly. 

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.